Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Agnieszka Michael, Kate Relph, Nicola Annels & Hardev Pandha. (2013) Prostate cancer vaccines. Expert Review of Vaccines 12:3, pages 253-262.
Read now
Read now
Articles from other publishers (24)
David J. Handelsman. (2022) History of androgens and androgen action. Best Practice & Research Clinical Endocrinology & Metabolism 36:4, pages 101629.
Crossref
Crossref
Qiuping Xiang, Chao Wang, Tianbang Wu, Cheng Zhang, Qingqing Hu, Guolong Luo, Jiankang Hu, Xiaoxi Zhuang, Lingjiao Zou, Hui Shen, Xishan Wu, Yan Zhang, Xiangqian Kong, Jinsong Liu & Yong Xu. (2021) Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry 65:1, pages 785-810.
Crossref
Crossref
Xishan Wu, Hui Shen, Yan Zhang, Chao Wang, Qiu Li, Cheng Zhang, Xiaoxi Zhuang, Chenchang Li, Yudan Shi, Yanli Xing, Qiuping Xiang, Jinxin Xu, Donghai Wu, Jinsong Liu & Yong Xu. (2021) Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist. Journal of Medicinal Chemistry 64:12, pages 8775-8797.
Crossref
Crossref
Reyaz ur Rasool, Ramakrishnan Natesan, Qu Deng, Shweta Aras, Priti Lal, Samuel Sander Effron, Erick Mitchell-Velasquez, Jessica M. Posimo, Shannon Carskadon, Sylvan C. Baca, Mark M. Pomerantz, Javed Siddiqui, Lauren E. Schwartz, Daniel J. Lee, Nallasivam Palanisamy, Goutham Narla, Robert B. Den, Matthew L. Freedman, Donita C. Brady & Irfan A. Asangani. (2019) CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discovery 9:11, pages 1538-1555.
Crossref
Crossref
Yajia Zhang, Sethuramasundaram Pitchiaya, Marcin Cieślik, Yashar S. Niknafs, Jean C.-Y. Tien, Yasuyuki Hosono, Matthew K. Iyer, Sahr Yazdani, Shruthi Subramaniam, Sudhanshu K. Shukla, Xia Jiang, Lisha Wang, Tzu-Ying Liu, Michael Uhl, Alexander R. Gawronski, Yuanyuan Qiao, Lanbo Xiao, Saravana M. Dhanasekaran, Kristin M. Juckette, Lakshmi P. Kunju, Xuhong Cao, Utsav Patel, Mona Batish, Girish C. Shukla, Michelle T. Paulsen, Mats Ljungman, Hui Jiang, Rohit Mehra, Rolf Backofen, Cenk S. Sahinalp, Susan M. Freier, Andrew T. Watt, Shuling Guo, John T. Wei, Felix Y. Feng, Rohit Malik & Arul M. Chinnaiyan. (2018) Analysis of the androgen receptor–regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nature Genetics 50:6, pages 814-824.
Crossref
Crossref
Qiuping Xiang, Yan Zhang, Jiaguo Li, Xiaoqian Xue, Chao Wang, Ming Song, Cheng Zhang, Rui Wang, Chenchang Li, Chun Wu, Yulai Zhou, Xiaohong Yang, Guohui Li, Ke Ding & Yong Xu. (2018) Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer. ACS Medicinal Chemistry Letters 9:3, pages 262-267.
Crossref
Crossref
Jey Sabith Ebron & Girish C. Shukla. (2016) Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3′-untranslated region. The Prostate 76:9, pages 834-844.
Crossref
Crossref
Lei Chang, Peter H. Graham, Jie Ni, Jingli Hao, Joseph Bucci, Paul J. Cozzi & Yong Li. (2015) Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance. Critical Reviews in Oncology/Hematology 96:3, pages 507-517.
Crossref
Crossref
Irfan A. Asangani, Vijaya L. Dommeti, Xiaoju Wang, Rohit Malik, Marcin Cieslik, Rendong Yang, June Escara-Wilke, Kari Wilder-Romans, Sudheer Dhanireddy, Carl Engelke, Mathew K. Iyer, Xiaojun Jing, Yi-Mi Wu, Xuhong Cao, Zhaohui S. Qin, Shaomeng Wang, Felix Y. Feng & Arul M. Chinnaiyan. (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510:7504, pages 278-282.
Crossref
Crossref
Terence W. Friedlander, Vy T. Ngo, Huan DongGayatri Premasekharan, Vivian Weinberg, Shaun Doty, Qiang ZhaoElizabeth G. Gilbert, Charles J. Ryan, Wen-Tien ChenPamela L. Paris. (2014) Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. International Journal of Cancer 134:10, pages 2284-2293.
Crossref
Crossref
Marta M. Millán & Santos Castañeda. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions
731
745
.
Donald W. RobinsonJr.Jr., Ning Zhao, Fitzroy Dawkins, Ming Qi & Dennis Revicki. (2013) Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials. Quality of Life Research 22:10, pages 2777-2786.
Crossref
Crossref
Isabel Heidegger, Petra Massoner, Iris E. Eder, Andreas Pircher, Renate Pichler, Friedrich Aigner, Jasmin Bektic, Wolfgang Horninger & Helmut Klocker. (2013) Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. The Journal of Steroid Biochemistry and Molecular Biology 138, pages 248-256.
Crossref
Crossref
Puranik Purushottamachar, Abhijit M. Godbole, Lalji K. Gediya, Marlena S. Martin, Tadas S. Vasaitis, Andrew K. Kwegyir-Afful, Senthilmurugan Ramalingam, Zeynep Ates-Alagoz & Vincent C. O. Njar. (2013) Systematic Structure Modifications of Multitarget Prostate Cancer Drug Candidate Galeterone To Produce Novel Androgen Receptor Down-Regulating Agents as an Approach to Treatment of Advanced Prostate Cancer. Journal of Medicinal Chemistry 56:12, pages 4880-4898.
Crossref
Crossref
Robert H. Bradbury, David G. Acton, Nicola L. Broadbent, A. Nigel Brooks, Gregory R. Carr, Glenn Hatter, Barry R. Hayter, Kathryn J. Hill, Nicholas J. Howe, Rhys D.O. Jones, David Jude, Scott G. Lamont, Sarah A. Loddick, Heather L. McFarland, Zaieda Parveen, Alfred A. Rabow, Gorkhn Sharma-Singh, Natalie C. Stratton, Andrew G. Thomason, Dawn Trueman, Graeme E. Walker, Stuart L. Wells, Joanne Wilson & J. Matthew Wood. (2013) Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorganic & Medicinal Chemistry Letters 23:7, pages 1945-1948.
Crossref
Crossref
R. FerraldeschiC. PezaroV. KaravasilisJ. de Bono. (2013) Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer. Annual Review of Medicine 64:1, pages 1-13.
Crossref
Crossref
Satoshi Yamamoto, Hiromi Kobayashi, Tomohiro Kaku, Katsuji Aikawa, Takahito Hara, Masuo Yamaoka, Naoyuki Kanzaki, Atsushi Hasuoka, Atsuo Baba & Mitsuhiro Ito. (2013) Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists. Bioorganic & Medicinal Chemistry 21:1, pages 70-83.
Crossref
Crossref
A. Cleve, K.-H. Fritzemeier, B. Haendler, N. Heinrich, C. Möller, W. Schwede & T. Wintermantel. 2012. Sex and Gender Differences in Pharmacology. Sex and Gender Differences in Pharmacology
543
587
.
Houtan Noushmehr, Simon G. Coetzee, Suhn K. Rhie, Chunli Yan & Gerhard A. Coetzee. 2013. Androgen-Responsive Genes in Prostate Cancer. Androgen-Responsive Genes in Prostate Cancer
59
84
.
Zoran Culig. 2013. Androgen-Responsive Genes in Prostate Cancer. Androgen-Responsive Genes in Prostate Cancer
177
185
.
Jie Ni, Paul J. Cozzi, Wei Duan, Sarah Shigdar, Peter H. Graham, Kearsley H. John & Yong Li. (2012) Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer and Metastasis Reviews 31:3-4, pages 779-791.
Crossref
Crossref
Sylvain Gauthier, Céline Martel & Fernand Labrie. (2012) Steroid derivatives as pure antagonists of the androgen receptor. The Journal of Steroid Biochemistry and Molecular Biology 132:1-2, pages 93-104.
Crossref
Crossref
Alex RawlinsonAza Mohammed, Marek Miller & Roger Kunkler. (2012) The role of enzalutamide in the treatment of castration-resistant prostate cancer. Future Oncology 8:9, pages 1073-1081.
Crossref
Crossref
Nima Sharifi & Richard J. Auchus. (2012) Steroid biosynthesis and prostate cancer. Steroids 77:7, pages 719-726.
Crossref
Crossref